First Affiliated Hospital of Ningbo University
宁波大学附属第一医院
Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at First Affiliated Hospital of Ningbo University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌3 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led1 open trial led
- Hepatocellular carcinoma肝细胞癌19 papers led
- Stomach cancer胃癌23 papers led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Osteosarcoma骨肉瘤3 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
- Neuroblastoma神经母细胞瘤1 paper led
- Multiple myeloma多发性骨髓瘤3 papers led
- Beta thalassaemiaβ 地中海贫血0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
- IgA nephropathyIgA 肾病2 papers led
Not listed for: Hepatoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Ningbo for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingRadiotherapy Combined With Endostatin and Capecitabine for NPC
- Phase
- Phase 2
- Started
- 2022-08
- Registry
- NCT05514275
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingImmune Score Based Radiomics in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2021-11
- Registry
- NCT05126160
Age 18 years to 70 years (registered criteria)
Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
- Single-cell transcriptomics and metabolomics reveal the potential role of ASRGL1 in metabolic reprogramming and invasion of nasopharyngeal carcinoma cells.
- High Expression of NLR and SII in patients With Nasopharyngeal Carcinoma as Potential Prognostic Observations.
- LINC00240 knockdown inhibits nasopharyngeal carcinoma progress by targeting miR-26a-5p.
All its trials on ClinicalTrials.gov, any status2
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.
- Open trials as a site
- 0
- led by another institution
2 hospitals in Ningbo for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Enrolling by invitationEfficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06715501
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Ningbo UniversityNingbo
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led1
All its trials on ClinicalTrials.gov, any status1
Cancer
Hepatocellular carcinoma
肝细胞癌Led 19 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Ningbo for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led19
- Identification of Androgen Receptor as a Molecular Docking Target for Survival and Response to Metformin-Induced Ferroptosis in Liver Cancer.
- Application Value of Enhanced CT Imaging Features in Predicting Vessels Encapsulating Tumor Clusters (VETC) Positivity in Hepatocellular Carcinoma.
- LZTR1 expression as a novel predictive biomarker for early recurrence of hepatocellular carcinoma.
- Identification and validation of an immune-related miRNA signature for predicting prognosis of hepatocellular carcinoma.
- NENF, as a Biomarker for the Development of NAFLD to Liver Cancer by Enhancing the Tumor-Like Stem Cell Properties of L02 Cells to Promote the Progression of NAFLD to Liver Cancer.
- Prognostic implication and immunotherapy response prediction of a novel ubiquitination-related gene signature in liver cancer.
- Developing risk models and subtypes of autophagy-associated LncRNAs for enhanced prognostic prediction and precision in therapeutic approaches for liver cancer patients.
- Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients.
- A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
- SpyGlass in Diagnosis of Hepatocellular Carcinoma with Right Hepatic Duct Tumor Thrombus Hemorrhage: A Case Report.
- Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.
- Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B.
- LncRNA BANCR promotes proliferation of hepatocellular carcinoma Huh-7 cells by activating Wnt/β-catenin signaling pathway.
- METTL3-mediated m6A methylation of ASPM drives hepatocellular carcinoma cells growth and metastasis.
- Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B.
- Reply to 'Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B'-A reply.
- The 5-year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
- Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
- LINC00922 promotes the proliferation, migration, invasion and EMT process of liver cancer cells by regulating miR-424-5p/ARK5.
Cancer
Stomach cancer
胃癌Led 23 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Ningbo for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingPerioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2023-07
- Registry
- NCT05970627
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led23
- Comprehensive analysis of scRNA-seq and bulk RNA-seq data via machine learning and bioinformatics reveals the role of lysine metabolism-related genes in gastric carcinogenesis.
- Molecular subtype of gastric cancer based on apoptosis-related genes reveals differential immune microenvironment and intratumoral microorganisms distribution.
- Unraveling the Anti-Tumor Effects and Molecular Mechanisms of Hairyvein Agrimonia Herb in Gastric Cancer Through Network Pharmacology and Experimental Validation.
- Non-coding RNAs in gastric cancer immunotherapy: mechanisms and clinical implications.
- tRF-34-86J8WPMN1E8Y2Q promotes the occurrence and development of gastric cancer by combining with LRAT.
- Risk factors and predictive nomogram for non-curative resection in patients with early gastric cancer treated with endoscopic submucosal dissection: a retrospective cohort study.
- Unveiling clinicopathologic features and outcomes for endoscopic submucosal dissection of early gastric cancer at gastric angulus in China.
- Machine learning to establish three sphingolipid metabolism genes signature to characterize the immune landscape and prognosis of patients with gastric cancer.
- DNA hypomethylation of INHBA promotes tumor progression and predicts prognosis and immune status of gastric cancer.
- Computed Tomography-Based Predictive Model for the Probability of Lymph Node Metastasis in Gastric Cancer: A Meta-analysis.
- Increased postoperative complications after laparoscopic gastrectomy in patients with preserved ratio impaired spirometry.
- tRF-33-P4R8YP9LON4VDP inhibits gastric cancer progression via modulating STAT3 signaling pathway in an AGO2-dependent manner.
- Identification of novel prognostic circRNA biomarkers in circRNA-miRNA-mRNA regulatory network in gastric cancer and immune infiltration analysis.
- Linc-ROR Regulates POU5F1 and SOX2 by Competitively Binding miR-145-5p to Affect the Proliferation and Migration of Gastric Cancer Cells.
- Transfer RNA-derived fragments as novel biomarkers of the onset and progression of gastric cancer.
- Construction and validation of a signature for T cell-positive regulators related to tumor microenvironment and heterogeneity of gastric cancer.
- Tumor budding as an indicator for lymph node metastasis and prognosis of early gastric cancer.
- CircRNA: A new class of targets for gastric cancer drug resistance therapy.
- The role of circular RNA hsa_circ_0001789 as a diagnostic biomarker in gastric carcinoma.
- FOXD2 regulations IQGAP3 mediated Ca2+ signaling pathway to facilitate gastric adenocarcinoma cell promotion.
- Clinical Experience of Intracorporeal Hand-sewn Anastomosis Following Totally Laparoscopic Pylorus-Preserving Gastrectomy for Middle-Third Early Gastric Cancer.
- Long non-coding RNA TUG1 promotes tumor progression and aggressiveness by regulating micro26b in gastric cancer.
- Reduced expression of circRNA hsa_circ_001888 in gastric cancer and its clinical significance.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Ningbo for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Cancer
Osteosarcoma
骨肉瘤Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
14 hospitals in Ningbo for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
- Silencing Lnc-HES1-10 Inhibits Osteosarcoma Cells Proliferation, Invasive Ability, and Metastasis.
- SMAR1 attenuates the stemness of osteosarcoma cells via through suppressing ABCG2 transcriptional activity.
- Resection of Giant Tumor of Chest Wall under Cardiopulmonary Bypass after Neoadjuvant Chemoradiotherapy: A Case Report.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Ningbo for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Ningbo for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Ningbo for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06049290
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
- GLYR1 transcriptionally regulates PER3 expression to promote the proliferation and migration of multiple myeloma.
- MicroRNA-138 promotes the progression of multiple myeloma through targeting paired PAX5.
- Hemorrhagic Necrotizing Enteritis Complicated with Talaromyces marneffei Infection After autoHSCT in Multiple Myeloma Patients.
All its trials on ClinicalTrials.gov, any status3
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Ningbo for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Ningbo for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led2
All its trials on ClinicalTrials.gov, any status4
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
Other diseases
IgA nephropathy
IgA 肾病Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Ningbo for IgA nephropathy346 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led2
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status2
Getting in touch
Name card to show staff or a driver
宁波大学附属第一医院
First Affiliated Hospital of Ningbo University
宁波
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.